Human psychopharmacology
May 2026
Juan Miguel Riestra, Yaxel Levin-Carrion, Roshan Sutar et al.
Treatment-resistant depression (TRD) remains a formidable challenge in psychiatry, with nearly one-third of patients with major depressive disorder (MDD) failing to respond adequately to first-line pharmacological treatments. Pathophysiology in MDD has highlighted the N-methyl-D-aspartate (NMDA) glutamatergic system as a promising therapeutic target. In 2022, the US Food and Drug Administration...
Human psychopharmacology
April 2011
Kerri Alexandra Schoedel, Nancy Chen, Annie Hilliard et al.
This study aimed to evaluate the abuse potential and cognitive effects of nabiximols (Sativex, GW Pharma Ltd. Salisbury, UK), an oromucosal spray primarily containing delta‐9‐tetrahydrocannabinol (THC) and cannabidiol (CBD). This was a single‐dose, randomized, double‐blind, crossover study comparing nabiximols (4, 8, and 16 consecutive sprays: 10.8, 21.6, and 43.2 mg THC, respectively) with...
Human psychopharmacology
January 2011
Paul D. Morrison, J M Stone
It is unknown if cannabis recreates the negative symptoms of schizophrenia. Healthy male volunteers (n = 22) completed two experimental sessions in which they received intravenous (IV) delta-9-tetrahydrocannabinol (THC) 2.5 mg or placebo in a randomised counterbalanced order. Negative symptoms were rated using the self-reported community assessment of psychic experiences scale (CAPE). Sedation...
Human psychopharmacology
April 2007
Daniel S O'Leary, Robert I Block, Julie A Koeppel et al.
Using an attention task to control cognitive state, we previously found that smoking marijuana changes regional cerebral blood flow (rCBF). The present study measured rCBF during tasks requiring attention to left and right ears in different conditions. Twelve occasional marijuana users (mean age 23.5 years) were imaged with PET using [15O]water after smoking marijuana or placebo cigarettes as...
Human psychopharmacology
July 2006
A C Parrott, J Rodgers, Tom Buchanan et al.
Non-drug factors such as ambient temperature can heighten the adverse effects of MDMA (3,4-methylendioxymethamphetamine) in animals. We assessed whether dancing and feeling hot on Ecstasy would be associated with more psychobiological problems in recreational users. In an internet study, 206 unpaid participants (modal age 16-24) reported that they had used recreational Ecstasy/MDMA. They...
Human psychopharmacology
June 2005
R M Milani, A C Parrott, F Schifano et al.
Cannabis is one of the most common 'co-drugs' for ecstasy users. The aim of the present study was to explore self-reported psychobiological problems in ecstasy polydrug users in relation to their pattern of cannabis use. Two hundred and eighty ecstasy polydrug users were allocated into five cannabis groups according to the frequency of their cannabis use. The control group comprised 121...